Markham, ON (March 24, 2025) - BOTOX COSMETIC® received Health Canada approval for the improvement in the appearance of platysma prominence in adults on March 4th, 2025.1 BOTOX COSMETIC® now has four aesthetic indication areas.
Patients are concerned about the appearance of the aging neck, which may negatively impact self perception.2-4 Despite the negative impact of platysma prominence, awareness that it can be treated is extremely low in Canada.5
“With Health Canada approval of BOTOX COSMETIC® for improvement of platysma prominence in adults, along with precise injection techniques and dosing guidelines, I am able to confidently provide my patients with a treatment option that can help them achieve their desired results,” said Dr. Vince Bertucci, board-certified dermatologist and pivotal clinical trial investigator. “My patients are often impressed by the positive impact that treating the neck and lower face can have. The neck and lower face have become a staple in my aesthetic consultations.”
The platysma muscle is a thin muscle that covers the neck and extends over the lower face. When this muscle is contracted it can cause the appearance of bands on the neck,6 which can also create a less defined jawline. Treatment with BOTOX COSMETIC® works beneath the surface to temporarily reduce the underlying muscle activity and improves the appearance of the bands connecting the neck and jaw.1 By injecting along the jawline and the vertical bands connecting the jaw and neck with one of the Health Canada approved doses of BOTOX COSMETIC® based on severity—26, 31, or 36 units—BOTOX COSMETIC® temporarily reduces underlying muscle activity.1
In Phase III clinical studies, the primary endpoint was met, demonstrating statistical significance for the improvement in appearance of platysma bands from baseline with BOTOX COSMETIC® versus placebo (p<0.0001).† This measure was based on both investigator and subject assessment.
†Primary endpoint was a multi-component ≥ 2-grade improvement based on both Investigator and Subject assessments of Platysma Band Severity at maximum contraction at day 14: 32% (n=64) vs 2% placebo (n=4) in Study 1; 31% (n=66) vs 0.5% placebo (n=1) in Study 2.1
FOR MORE INFORMATION:
Please consult the BOTOX COSMETIC® Product Monograph available at www.allerganaesthetics.ca for important information relating to adverse reactions, drug interactions (particularly aminoglycosides or neuromuscular blocking agents), and dosing information.
Adverse events or Product Quality Complaints should be reported to Allergan Aesthetics, an AbbVie company at capq@abbvie.com.
©2025 AbbVie. All rights reserved.
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.ca or follow us on Instagram at @allerganaestheticsCA.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com.
References
1. BOTOX® Cosmetic Product Monograph, March 2025.
2. Calisti A, et al. Dermatol Surg 2017;43(9):1186–89
3. Swift A et al. Aesthet Surg J. 2021 Sep 14;41(10):1107-1119.
4. Baumann L, et al. Dermatol Surg 2019;45(1):124–30
5. Allergan Aesthetics – Platysma Bands Global Assessment - Patient Quantitative Report V1.0. Date of preparation 24 May 2021.
6. Chen DL, et al. J Drugs Dermatol. 2015;14:931